In this monthly news roundup, we take a look back at top moments from the pharmaceutical industry. It’s time to reflect on ...

Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.

New therapy reprograms immune cells inside tumors to attack cancer, bypassing traditional cell therapy manufacturing ...

A new personalized mRNA melanoma vaccine developed by Moderna and Merck is showing promising results, cutting the risk of cancer recurrence nearly in half for high-risk patients.

Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest ...

A fresh outbreak in India has raised regional health concerns, prompting warnings for travellers and renewed focus on Malaysia’s preparedness.

Some periods of history are so bizarre that even if you’ve lived through them, looking back on them feels surreal, as though ...

The University of Auckland is hosting the research as part of the Global COVID Vaccine Safety (GCoVS) Project. Scientists ...

After moving sharply lower on tariff fears to start the week, stocks rallied as most economic indicators point to an economy that’s growing strongly. An in-line reading on the November PCE inflation ...

Moderna, Inc. vs. Novavax, Inc.: cost cuts, vaccine pipeline catalysts, and valuations. Click for this comparison of NVAX and ...

On this World Cancer Day, we look at where research and availability stand for cancer vaccines.

The latest firm to top up its venture capital coffers is Austin, Texas-based Santé Ventures, which on Monday announced its ...